

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

APR 22 2004

AMGEN[®]

Amgen Inc.
Law Department
1201 Amgen Court West
Seattle, WA 98119

Telephone: (206) 265-7145
Facsimile: 206-233-0644

FAX MESSAGE - PLEASE DELIVER IMMEDIATELY

Send to: United States Patent Office FAX: 703-872-9306
ATTN: TC1600

From: James E. Klaniecki Date: April 22, 2004
Corporate Counsel/Patent Attorney
206-265-7000 Ext. 57145

No. of pages including this page: 10

Re: US Patent Application Serial No: 09/448,378
Filed: November 23, 1999
For: METHODS OF USING FLT3-LIGAND FOR AUGMENTING
AN IMMUNE RESPONSE FOR THE TREATMENT OF
CANCER (AS AMENDED)


The following documents are being facsimile transmitted to the USPTO, ATTN:
TC1600:

Amendment Transmittal Letter (1 page) (+ copy);
Amendment and Reply (7 pages)

If transmission problems occur contact Nanci Kertson at 206-587-0430 Ext. 54449.


CONFIDENTIALITY NOTICE: This communication (including any accompanying page(s)) is intended solely for the use of the individual or entity named above and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, you are hereby notified that any copying, distribution or other unauthorized use of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

PATENT APPLICATION

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL				Attorney's Docket No: 2836-D			
Serial No. 09/448,378		Filing Date Nov. 23, 1999		Examiner P. Gambel		Group Art Unit 1644	
In Re Application of Kenneth Brasel et al.							
For METHODS OF USING FLT3-LIGAND FOR AUGMENTING AN IMMUNE RESPONSE FOR THE TREATMENT OF CANCER (as amended)							
TO THE COMMISSIONER FOR PATENTS:							
<input checked="" type="checkbox"/> Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a): <input type="checkbox"/> One month of original due date (\$110.00) <input type="checkbox"/> Two months of original due date (\$420.00) <input checked="" type="checkbox"/> Three months of original due date (\$950.00) <input type="checkbox"/> Four months of original due date (\$1,480.00) <input type="checkbox"/> Five months of original due date (\$2,010.00)							
<input checked="" type="checkbox"/> A response in connection with the matter for which this extension is requested: <input checked="" type="checkbox"/> Is filed herewith. <input type="checkbox"/> has been filed. <input type="checkbox"/> The response is the filing of a continuing prosecution application, the prior application having an express abandonment conditioned on the granting of a filing date to the continuing application.							
<input checked="" type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required. <input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:							
CLAIMS AS AMENDED							
(1)	(2) Claims remaining After amendment	(3)	(4) Highest number Previously paid for	(5) No. of Extra claims present	(6) Rate	(7) Additional Fee	
Total Claims		Minus	=	0	x \$18	=	\$ 0.00
Indep. Claims		Minus	=	0	x \$86	=	0.00
<input type="checkbox"/> First Appearance of a multiple dependent claim					+	\$290	= 0.00
Total Additional Fee for this Amendment						\$0.00	
<p>* If the entry in column 2 is less than the entry in column 4, write "0" in column 5. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col 1. of a prior amendment or the number of claims originally filed.</p> <p><input type="checkbox"/> The following other fees are incurred by the accompanying papers. <input type="checkbox"/> Other: _____</p> <p><input checked="" type="checkbox"/> Please charge Deposit Account No. 09-0089 in the name of Immunex Corporation in the amount of \$950. A duplicate copy of this petition is attached.</p> <p><input checked="" type="checkbox"/> If an additional extension of time is required, please consider this a request therefore.</p> <p><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 09-0089.</p>							
Please Send Future Correspondence To:							
Immunex Corporation Law Department 1201 Amgen Court West Seattle, Washington 98119-3105 (206) 265-7000				 James E. Klaniecki Attorney for Applicants) Registration No.: 38,207 Phone: (206) 265-7145 Date: April 22, 2004			

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date listed below.

April 22, 2004 
 Date Signature

Appl. No. 09/448,378
Amdt. dated April 22, 2004
Response to OA of November 5, 2003

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

APR 22 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:	Docket No.:	2836-D
Kenneth Brasel et al.		
Serial No: 09/448,378	Group Art Unit:	1644
Filed: November 23, 1999	CPA Filed:	June 28, 2001
For: METHODS OF USING FLT3-LIGAND FOR AUGMENTING AN IMMUNE RESPONSE FOR THE TREATMENT OF CANCER (AS AMENDED)	Examiner:	P. Gambel, PhD.

AMENDMENT AND REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. Introductory Comments

Sir:

In response to the Office Action mailed November 5, 2003 and having a due date of February 5, 2004, Applicants submit the following Amendment and Reply. This response is accompanied by a Petition for a three-month extension of time and requisite fee. Applicants respectfully request reconsideration and allowance of the claims.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.